Nanotechnology Now

Our NanoNews Digest Sponsors



Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > Tekmira Pharmaceuticals Collaborator National Cancer Institute Presents Anti-Tumor Data at Liver Cancer Conference

Abstract:
Tekmira Also Presents at Charles River Biotech Symposium

Tekmira Pharmaceuticals Collaborator National Cancer Institute Presents Anti-Tumor Data at Liver Cancer Conference

VANCOUVER, BC, Canada | Posted on September 8th, 2008

Tekmira Pharmaceuticals Corporation (TSX:TKM) announced today that one of its collaborators, the National Cancer Institute (NCI), has presented promising pre-clinical data treating liver cancer using small interfering RNA (siRNA) enabled by Tekmira's SNALP (stable nucleic acid-lipid particles) delivery technology.

Dr. Yun-Han Lee, a member of the NCI's Laboratory of Experimental Carcinogenesis (LEC), presented the data at the International Liver Cancer Association (ILCA) meeting being held in Chicago, IL September 5-7, 2008.

Scientists at the LEC and the Surgery Branch of the NCI worked in collaboration with Tekmira scientists to develop siRNA to silence the CSN5 gene. The CSN5 siRNA delivered systemically using Tekmira's SNALP technology resulted in a significant reduction in tumor burden in human hepatocellular carcinoma (HCC) tumor bearing mice.

CSN5 could represent a novel therapeutic target to treat HCC. Down regulation of CSN5 using siRNA increases apoptosis (programmed cell death) by restoring levels of tumor suppressor proteins p53 and p27. Silencing the CSN5 gene has also been shown to decrease a certain population of cells thought to be cancer stem cells. Research suggests that it is critical to destroy this population of cancer stem cells within a tumor to prevent the re-growth of the tumor.

Dr. Mark J. Murray, Tekmira's President and CEO, said, "We have had a very successful collaboration with NCI over the past two years. By combining their expertise in identifying novel cancer genes and our expertise in designing and delivering siRNA molecules, we have been able to generate this promising data targeting the CSN5 gene."

Tekmira and NCI are continuing to collaborate on identifying novel cancer genes and demonstrating anti-tumor activity by silencing these genes through RNA interference.

Presentation at Charles River Biotech Symposium

In addition to the NCI presentation at the ILCA meeting, Tekmira is also presenting data at the Charles River Biotech Symposium (CRBS). Dr. Ian MacLachlan, Tekmira's Chief Scientific Officer, is presenting at CRBS September 9, 2008.

Dr. MacLachlan's presentation will focus on Tekmira's advancement of its SNALP delivery technology and its chemical modification technology that can minimize the immune stimulatory effects of siRNA. Tekmira's SNALP technology is designed to overcome the challenges of systemic delivery of siRNA by designing lipid nanoparticles with the appropriate characteristics to deliver siRNA to target tissues and into cells.

Tekmira's first two product candidates, ApoB SNALP and PLK1 SNALP, are based on its SNALP technology. Tekmira has also licensed its SNALP technology to leading industry partners including Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), Roche (SWX:ROG) and Merck & Co. (NYSE:MRK). Alnylam has also provided access to Tekmira's technology to certain of its partners, including Regulus Therapeutics and Takeda Pharmaceutical Company Limited.

About RNAi and SNALP

RNAi drugs have the potential to treat human diseases by "switching-off" disease causing genes. The technology, representing one of the most promising and rapidly advancing frontiers in biology and drug discovery, was awarded the 2006 Nobel Prize for Physiology or Medicine. RNAi drugs, such as siRNA, require delivery technology to be administered systemically. In preclinical studies, Tekmira's SNALP (stable nucleic acid-lipid particles) technology has been shown to be a safe and effective way to deliver RNAi drugs to disease sites. Tekmira believes it has a leading intellectual property position in the field of siRNA delivery.

####

About Tekmira Pharmaceuticals Corporation
Tekmira Pharmaceuticals Corporation is a biopharmaceutical company focused on advancing novel RNAi products and providing its leading lipid nanoparticle delivery technology to pharmaceutical partners. Further information about Tekmira can be found at www.tekmirapharm.com. Tekmira is based in Vancouver, B.C.

Forward-Looking Statements and Information

There are forward-looking statements and information contained herein that are not based on historical fact, including, without limitation, statements containing the words "believes", "may", "plans", "will", "estimate", "continue", "anticipates", "intends", "expects", and similar expressions, and the negative of such expressions. These statements are only predictions.

Forward-looking statements and information should be considered carefully. Undue reliance should not be placed on forward-looking statements and information as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. By their nature, forward-looking statements and information involve numerous assumptions, known and unknown risks and uncertainties, both general and specific, which contribute to the possibility that the predictions, forecasts, projections and other forward-looking statements and information will not occur and may cause actual results or events to differ materially from those anticipated in such forward-looking statements and information.

There are also other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements and information. Such factors include, among others, the stage of development of Tekmira, lack of product revenues, additional capital requirements, the need to obtain regulatory approval to commence clinical trials, risks associated with the completion of clinical trials and obtaining regulatory approval to market Tekmira's products, the safety and efficacy of Tekmira's products, the ability to protect Tekmira's intellectual property and dependence on collaborative partners.

A more complete discussion of the risks and uncertainties facing Tekmira appears in Tekmira's management information circular dated May 1, 2008 available at www.sedar.com. Tekmira disclaims any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements or information contained herein to reflect future results, events or developments, except as required by law.

For more information, please click here

Contacts:
Tekmira Pharmaceuticals Corporation - Investors
Ian Mortimer
Executive Vice President and Chief Financial Officer
(604) 419-3200
or
Longview Communications Inc. - Media
Josh Pekarsky
(604) 694-6030

Copyright © Marketwire

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Scientists reveal breakthrough in optical fiber communications December 21st, 2014

Atom-thick CCD could capture images: Rice University scientists develop two-dimensional, light-sensitive material December 20th, 2014

Oregon researchers glimpse pathway of sunlight to electricity: Collaboration with Lund University uses modified UO spectroscopy equipment to study 'maze' of connections in photoactive quantum dots December 19th, 2014

Instant-start computers possible with new breakthrough December 19th, 2014

Nanomedicine

Creation of 'Rocker' protein opens way for new smart molecules in medicine, other fields December 18th, 2014

Iranian Researchers Produce Electrical Pieces Usable in Human Body December 18th, 2014

Unraveling the light of fireflies December 17th, 2014

First Home-Made Edible Herbal Nanodrug Presented to Pharmacies across Iran December 17th, 2014

Announcements

Scientists reveal breakthrough in optical fiber communications December 21st, 2014

Atom-thick CCD could capture images: Rice University scientists develop two-dimensional, light-sensitive material December 20th, 2014

Oregon researchers glimpse pathway of sunlight to electricity: Collaboration with Lund University uses modified UO spectroscopy equipment to study 'maze' of connections in photoactive quantum dots December 19th, 2014

Instant-start computers possible with new breakthrough December 19th, 2014

Events/Classes

Bruker Introduces BioScope Resolve High-Resolution BioAFM System: Featuring PeakForce Tapping for Quantitative Bio-Mechanical Property Mapping December 16th, 2014

TCL Launches World’s Most Advanced TV in the World’s Largest Market: New Quantum Dot TVs with Color IQ™ Optics Deliver OLED-Quality Color at a Fraction of the Price December 15th, 2014

Stanford team combines logic, memory to build a 'high-rise' chip: Today circuit cards are laid out like single-story towns; Futuristic architecture builds layers of logic and memory into skyscraper chips that would be smaller, faster, cheaper -- and taller December 15th, 2014

PETA science consortium to present at Society for Risk Analysis meeting December 10th, 2014

Research partnerships

Scientists reveal breakthrough in optical fiber communications December 21st, 2014

Oregon researchers glimpse pathway of sunlight to electricity: Collaboration with Lund University uses modified UO spectroscopy equipment to study 'maze' of connections in photoactive quantum dots December 19th, 2014

Unraveling the light of fireflies December 17th, 2014

Scientists trace nanoparticles from plants to caterpillars: Rice University study examines how nanoparticles behave in food chain December 16th, 2014

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More










ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE